In silico clinical trials for pediatric orphan diseases

To date poor treatment options are available for patients with congenital pseudarthrosis of the tibia (CPT), a pediatric orphan disease. In this study we have performed an in silico clinical trial on 200 virtual subjects, generated from a previously established model of murine bone regeneration, to tackle the challenges associated with the small, pediatric patient population. Each virtual subject was simulated to receive no treatment and bone morphogenetic protein (BMP) treatment. We have shown that the degree of severity of CPT is significantly reduced with BMP treatment, although the effect is highly subject-specific. Using machine learning techniques we were also able to stratify the virtual subject population in adverse responders, non-responders, responders and asymptomatic. In summary, this study shows the potential of in silico medicine technologies as well as their implications for other orphan diseases.

[1]  R. Margraf,et al.  Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1 , 2015, Journal of Medical Genetics.

[2]  Jonathan C. Craig,et al.  Clinical trials in children. , 2015, British journal of clinical pharmacology.

[3]  Jos Vander Sloten,et al.  Occurrence and Treatment of Bone Atrophic Non-Unions Investigated by an Integrative Approach , 2010, PLoS Comput. Biol..

[4]  S. Mundlos,et al.  Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin , 2008, BMC medicine.

[5]  M. Lazebnik,et al.  Safe magnetic resonance imaging scanning of patients with cardiac rhythm devices: a role for computer modeling. , 2013, Heart rhythm.

[6]  Pras Pathmanathan,et al.  Ensuring reliability of safety-critical clinical applications of computational cardiac models , 2013, Front. Physiol..

[7]  J. Carey,et al.  Double inactivation of NF1 in tibial pseudarthrosis. , 2006, American journal of human genetics.

[8]  I. Alexander,et al.  A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast‐like cells , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Peter A Merkel,et al.  Clinical research for rare disease: opportunities, challenges, and solutions. , 2009, Molecular genetics and metabolism.

[10]  Jeffrey Shuren,et al.  An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. , 2017, The New England journal of medicine.

[11]  Jiang Yao,et al.  Determining the most important cellular characteristics for fracture healing using design of experiments methods. , 2008, Journal of theoretical biology.

[12]  Liesbet Geris,et al.  Size Does Matter: An Integrative In Vivo-In Silico Approach for the Treatment of Critical Size Bone Defects , 2014, PLoS Comput. Biol..

[13]  M. Viceconti,et al.  Patient-specific finite element estimated femur strength as a predictor of the risk of hip fracture: the effect of methodological determinants , 2016, Osteoporosis International.

[14]  H Van Oosterwyck,et al.  Designing optimal calcium phosphate scaffold-cell combinations using an integrative model-based approach. , 2011, Acta biomaterialia.

[15]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[16]  W. Friess,et al.  Collagen sponges for bone regeneration with rhBMP-2. , 2003, Advanced drug delivery reviews.

[17]  C. Cobelli,et al.  In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[18]  Ralf-Dieter Hilgers,et al.  Directions for new developments on statistical design and analysis of small population group trials , 2016, Orphanet Journal of Rare Diseases.

[19]  Aaron Schindeler,et al.  Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). , 2008, Bone.

[20]  B. S. Richards,et al.  rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia , 2016, Journal of pediatric orthopedics.

[21]  Campbell O. Webb,et al.  Picante: R tools for integrating phylogenies and ecology , 2010, Bioinform..

[22]  Paul F. Reynolds,et al.  The Role of Modeling and Simulation , 2008 .

[23]  In Ho Choi,et al.  Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. , 2006, The Journal of bone and joint surgery. American volume.

[24]  M. Karlsson,et al.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.

[25]  J. Rueger,et al.  Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. , 2011, The Journal of bone and joint surgery. British volume.

[26]  Liesbet Geris,et al.  Oxygen as a critical determinant of bone fracture healing-a multiscale model. , 2015, Journal of theoretical biology.

[27]  Aris Angelis,et al.  Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. , 2015, Health policy.

[28]  David Gavaghan,et al.  Multi-scale computational modelling in biology and physiology , 2007, Progress in Biophysics and Molecular Biology.

[29]  L. Geris,et al.  Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study , 2016, Scientific Reports.

[30]  M. Viceconti,et al.  Biomechanical robustness of a new proximal epiphyseal hip replacement to patient variability and surgical uncertainties: a FE study. , 2012, Medical engineering & physics.

[31]  G. Clermont,et al.  In silico design of clinical trials: A method coming of age , 2004, Critical care medicine.

[32]  John G. Holden,et al.  A fractal approach to dynamic inference and distribution analysis , 2013, Front. Physio..

[33]  C. Wahlestedt,et al.  Orphan diseases: state of the drug discovery art , 2017, Wiener Medizinische Wochenschrift.

[34]  B. Dohin,et al.  Masquelet’s procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis , 2012, Journal of children's orthopaedics.

[35]  Marco Viceconti,et al.  In silico clinical trials: how computer simulation will transform the biomedical industry , 2016 .

[37]  R. Atit,et al.  The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. , 1999, The Journal of investigative dermatology.

[38]  Y. Tabata,et al.  Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. , 2005, Biomaterials.